Dare Bioscience Seeks Stockholder Approval for Warrant Exercise That Could Dilute Shares by 45%
DARE sits 17% above its 52-week low of $0.69 on light trading volume (0.2× avg).
Summary
Dare Bioscience is seeking stockholder approval to allow the exercise of 8.9 million warrants from its August 2026 financing. If approved and fully exercised, the warrants would dilute existing shareholders by approximately 45% and generate $12.4 million in cash proceeds.
Key Events · Corporate Governance and Compliance · DARE
-
Warrant Exercise Approval Sought
Stockholders are being asked to approve the exercisability of 8,934,345 warrants issued in the August 2026 financing. The warrants cannot be exercised without this approval.
-
45% Potential Dilution
If all warrants are exercised, the company would issue 8,934,345 shares, representing approximately 45% of the 19,669,083 shares outstanding as of September 18, 2026.
-
$12.4M Potential Proceeds
If all warrants are exercised for cash, the company would receive aggregate gross proceeds of approximately $12.4 million. No assurance is given that any warrants will be exercised.
-
Nasdaq 20% Rule Compliance
The stockholder vote is required under Nasdaq Listing Rule 5635(d) because the warrant exercise price of $1.37 was below the market price at the time of the financing, and the issuance would exceed 19.99% of outstanding shares.
Analysis · DARE · Life Sciences
Dare Bioscience is asking stockholders to approve the exercisability of 8.9 million warrants issued in its August 2026 financing. If approved and all warrants are exercised for cash, the company would issue approximately 45% more shares and receive $12.4 million in proceeds. The warrants cannot be exercised without this approval, and the company is obligated to hold stockholder meetings every 60 days until approval is obtained, which would drain cash and management attention. The vote is required under Nasdaq's 20% Rule because the warrant exercise price of $1.37 was below the market price at the time of the financing. This is a critical governance event for a company already facing going concern doubt and a Nasdaq delisting notice.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9M. The 52-week trading range was $0.69 to $3.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.